Phesi and Sensyne Health Collaborate to Advance Development of Synthetic Arms in Trials

Phesi Inc. has announced it has entered into a collaboration with clinical AI technology company, Sensyne Health, which is making an equity investment of $10 million in Phesi. The investment will be used to accelerate Phesi’s and Sensyne’s product roadmaps.

For Phesi this means further development of its trial planning, protocol design and investigator site selection platform, featuring ClinSite. For Sensyne, this means the growth and ‘industrialization’ of its data platform and forms part of the company’s US market growth strategy. The collaboration will see Sensyne anonymized real-world evidence data set of 6.1 million patients analyzed alongside Phesi’s data, which today covers 30 million clinical trial subjects.

Together, the companies will provide an enhanced offering of clinical trial and real-world data predictive analytics, enabling life sciences organizations to quickly and safely determine the feasibility of replacing or supplementing a comparator or placebo arm with a synthetic arm.

The agreement between Phesi and Sensyne Health was completed on January 4th, 2021; Dr Gen Li, Phesi’s CEO and Founder, also becomes a strategic advisor to the Board of Sensyne. 

For more information, click here.